InFo Neurologie & Psychiatrie

, Volume 16, Issue 4, pp 42–50

Therapie nach Einführung der neuen Immuntherapeutika

Schubförmige Multiple Sklerose
zertifizierte fortbildung

Zusammenfassung

Die Einführung zahlreicher neuer Immuntherapeutika ermöglicht eine zunehmend bessere medikamentöse Therapie der Multiplen Sklerose (MS), die individueller auf den Patienten abgestimmt werden kann. Allerdings erfordert der Einsatz vieler Medikamente, die immer häufiger auch in Folge eingesetzt werden, ein individuelles Monitoring und Risikomanagement. In den letzten Monaten wurden drei weitere neue Immuntherapeutika zur Behandlung der schubförmig verlaufenden MS zugelassen.

Literatur

  1. 1.
    Scannevin R. Cytoprotective Role of the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway in the Central Nervous System. Journal of Pharmacology and Experimental Therapeutics. 2012 Apr 1;341(1):274–284PubMedCrossRefGoogle Scholar
  2. 2.
    Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. N Engl J Med. 2012 Sep 20;367(12):1098–1107.PubMedCrossRefGoogle Scholar
  3. 3.
    Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. N Engl J Med. 2012 Sep 20;367(12):1087–97.PubMedCrossRefGoogle Scholar
  4. 4.
    Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. The Lancet. Elsevier Ltd; 2008;372(9648):1463–72.CrossRefGoogle Scholar
  5. 5.
    van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy. N Engl J Med. 2013 Apr 25;368(17):1658–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Ermis U, Weis J, Schulz JB. PML in a Patient Treated with Fumaric Acid. N Engl J Med. 2013 Apr 25;368(17):1657–8.PubMedCrossRefGoogle Scholar
  7. 7.
    O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. N Engl J Med. 2011 Oct 6;365(14):1293–303.PubMedCrossRefGoogle Scholar
  8. 8.
    Confavreux C, O’Connor P, Comi C, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay J-L, Dukovic D, Truffinet D, Kappos L for the TOWER Trial Group. Oral teriflunomide for patients with relapsing multiplesclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Neurology. Elsevier Ltd; 2014 Jan 22;:1–10.Google Scholar
  9. 9.
    Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple Sclerosis Journal. 2013 Oct 14; 0(0):1–12.Google Scholar
  10. 10.
    Confavreux C, Li DK, Freedman MS, Truffinet P, Benzerdjeb H, Wang D, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Multiple Sclerosis Journal. 2012 Sep 1;18(9):1278–89.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Warnke C, Mayer Zu Horste G, Hartung HP et al. Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2009 May 26;(5):333–40.PubMedCentralPubMedGoogle Scholar
  12. 12.
    www.iqwig.de:download:A13-38_Teriflunomid_Kurzfassung_Nutzenbewertung-35a-SGB-V. 2013 Dec 20;:1–5.Google Scholar
  13. 13.
    Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. 2012 Mar 1;83(3):298–304.CrossRefGoogle Scholar
  14. 14.
    Cox AL. Reconstitution of the lymphocyte compartment after lymphocyte depletion: A key issue in clinical immunology. Eur J Immunol. 2005 Nov;35(11):3332–3342.PubMedCrossRefGoogle Scholar
  15. 15.
    Cohen JA, Coles A, Arnold DL et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. The Lancet. Elsevier Ltd; 2012 Nov 4;380(9856):1819–28.CrossRefGoogle Scholar
  16. 16.
    Coles A, Twyman CL, Arnold DL et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. The Lancet. Elsevier Ltd; 2012 Nov 24;380(9856):1829–39.CrossRefGoogle Scholar
  17. 17.
    Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial. Neurology. 2012 Apr 3;78(14):1069–78.PubMedCrossRefGoogle Scholar
  18. 18.
    Costelloe L, Jones J, Coles A. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Review of Neurotherapeutics. 2012 Mar;12(3):335–41.PubMedCrossRefGoogle Scholar
  19. 19.
    Robert Koch Institut. Hinweise zu Impfungen für Patienten mit Immundefizienz. Epid Bull/Sonderdruck. 2005 Nov; 1-12.Google Scholar
  20. 20.

Copyright information

© Urban & Vogel 2014

Authors and Affiliations

  1. 1.Klinikum rechts der IsarNeurologischen Klinik und Poliklinik der Technischen Universität MünchenMünchenDeutschland

Personalised recommendations